Telehealth companies like Noom, Found, and Hims & Hers are aggressively marketing 'microdosed' GLP-1 agonists, such as semaglutide and tirzepatide, for weight loss and metabolic health. These programs utilize compounded drugs at doses lower than FDA-approved standards, claiming benefits like reduced inflammation and cognitive risk. However, medical experts emphasize that robust clinical evidence supporting the efficacy or safety of these very low doses is currently lacking.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.